David Craig's The New Rules of Biotech: A Founder's Guide to Building Great Companies is now available in hardcover ($29.99) and as an audiobook on Google Play, joining the paperback ($21.99) and Kindle ($11.99) editions already on sale through Amazon. The book provides a practical playbook for founders, investors, board members, and operators navigating the current biotech environment, where capital is scarce, FDA expectations have risen, and the Inflation Reduction Act has altered drug economics.
The book opens from the premise that the biotech playbook written for 2021 no longer works. Craig draws on his experience as founder and CEO of Sarcomatrix Therapeutics Corp. to outline how to choose between platform and asset companies, select affordable modalities, raise seed rounds tied to milestones, and use non-dilutive capital strategically. It covers IND-enabling work, CMC, clinical decisions, term sheets, boards, business development, and exits like acquisitions and IPOs without sentimentality.
Each chapter includes takeaways for operators and separate insights for investors and advisors. The audiobook offers the same material for listening on the move. Craig notes the book's origin in a family connection to a rare genetic muscle disease, RYR-1 related congenital muscular dystrophy, which informs the argument that biotech company building carries a responsibility beyond returns.
"Founders and operators take in ideas in different ways," said Craig. "The hardcover is there for the people who want a durable copy on the desk, the paperback and Kindle for everyone else, and the audiobook on Google Play for those who prefer to listen on the move."
The book is published by D. Craig Consulting LLC and available at Amazon in hardcover, paperback, Kindle, and audiobook on Google Play.
